Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: Results of the Groupe d'etudes des Lymphomes de l'Adulte H89 trial

Blood

Volumn 95, Issue 7, 2000, Pages 2246-2252

  Fermé, Christophe ^a   Sebban, Catherine ^b   Hennequin, Christophe ^b   Divine, Marine ^b   Lederlin, Pierre ^b   Gabarre, Jean ^b   Ferrant, Augustin ^b   Caillot, Denis ^b   Bordessoule, Dominique ^b   Brice, Pauline ^b   Moullet, Isabelle ^b   Berger, Françoise ^b   Lepage, Eric ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; FEMALE; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; SURVIVAL TIME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOXORUBICIN; HODGKIN DISEASE; HUMANS; MECHLORETHAMINE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROCARBAZINE; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL RATE; VINBLASTINE; VINCRISTINE;

EID: 12944329903     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992;10:210.
2. Bakemeier RF, Anderson JR, Costello W, et al. BCVPP chemotherapy for advanced Hodgkin's disease. Ann Intern Med. 1984;101:447.
3. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. Ann Intern Med. 1986;104:739.
4. Klimo P, Connors JM. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV hybrid program. Semin Hematol 1988;25(suppl 2): 4.
5. Fabian CJ, Mansfield CM, Dahlberg S, et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin's disease. A Southwest Oncology Group randomized study. Ann Intern Med. 1994;120:903.
6. Prosnitz LR, Farber LR, Kapp DS, Bertino JR, Nordlund M, Lawrence R. Combined modality therapy for advanced Hodgkin's disease: long-term follow-up data. Cancer Treat Rep. 1982;66: 871.
7. Prosnitz LR, Farber LR, Kapp DS, et al. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data. J Clin Oncol. 1988;6:603.
8. Rosenberg SA, Kaplan HS. The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984. Int J Radial Oncol Biol Phys. 1985;11:5.
9. Yelle L, Bergsagel D, Basco V, et al. Combined modality therapy of Hodgkin's disease: 10-year results of National Cancer Institute of Canada clinical trials group multicenter clinical trial. J Clin Oncol. 1991;9:1983.
10. Pavlovsky S, Santarelli MT, Sackmann Muriel F, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage III-IV A & B Hodgkin's disease. Ann Oncol. 1992;3:533.
11. Assouline D, Adelein P, Jaubert J, et al. Advanced stage Hodgkin's disease (HD): long term results of the LMS 80 protocol [abstract]. Proc Am Soc Clin Oncol. 1993;12:381.
12. Diehl V, Loeffler M, Pfreundschuh M, et al, for the German Hodgkin's Study Group. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease. Ann Oncol. 1995;6:901.
13. Coleman M, Ralla S, Propoert KJ, et al. Augmented therapy of extensive Hodgkin's disease: radiation to known disease or prolongation of induction chemotherapy did not improve survival. Results of a Cancer and Leukemia Group B Study. Int J Radiat Oncol Biol Phys. 1998;41:639.
14. Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. J Clin Oncol. 1998;16:818.
15. Fermé C, Bastion Y Lepage E, et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol. 1995;6:543.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457.
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163.
18. Cox DR, Oakes D. Analysis of Survival Data. New York, NY: Chapman & Hall; 1984.
19. Hasenclever D, Diehl V, for the International Prognostic Factors Project on Advanced Hodgkin's Disease. A prognostic score for advanced Hodgkin's disease. N Engl J Med. 1998; 339:1506.
20. Fermé C, Lepage E, Brice P, et al. Combined chemotherapy-radiotherapy in advanced Hodgkin's disease: results of a prospective clinical trial with 70 stage IIIB-IV patients. Int J Radiat Oncol Biol Phys. 1993;26:397.
21. DeVita VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970;73:881.
22. Yahalom J, Ryu J, Straus DJ, et al. Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin s disease treated with alternating chemotherapy combinations. J Clin Oncol. 1991;9:2193.